Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia

@article{Khodadoust2016ClinicalAO,
  title={Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia},
  author={Michael S Khodadoust and Bi-hui Luo and Bruno Campelo Medeiros and Ryan C Johnson and Mark D Ewalt and A S Schalkwyk and Charles D. Bangs and Athena M Cherry and Shuka Arai and Daniel Alan Arber and James L Zehnder and Jason Gotlib},
  journal={Leukemia},
  year={2016},
  volume={30},
  pages={947-950}
}
In the World Health Organization classification, fibroblast growth factor receptor 1 (FGFR1)-rearranged myeloid and lymphoid neoplasms are included with rearrangements involving plateletderived growth factor receptor α and β. FGFR1-rearranged neoplasms are acquired hematopoietic stem cell disorders that usually present as an eosinophilia-associated myeloproliferative neoplasm, acute leukemia and/or lymphoblastic lymphoma. Among the 15 different FGFR1 fusion partners that have been identified… CONTINUE READING
9 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Similar Papers

Loading similar papers…